NEOSCAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEOSCAN (NEOSCAN).
Neoscan (technetium Tc 99m bicisate) is a radiopharmaceutical agent used for brain imaging. It forms a lipophilic complex that crosses the blood-brain barrier and is retained in brain tissue proportional to regional cerebral blood flow. Its mechanism involves the transport across the blood-brain barrier and intracellular trapping by esterase-mediated hydrolysis.
| Metabolism | Not extensively metabolized; the complex is likely hydrolyzed by esterases in the brain and other tissues. |
| Excretion | Neoscan (technetium Tc 99m medronate) is eliminated primarily via the renal route, with 50-70% of the administered dose excreted unchanged in the urine within 24 hours. The remainder is distributed to bone and soft tissues, with negligible biliary or fecal elimination (<5%). |
| Half-life | The terminal elimination half-life is approximately 6 hours (range 4-8 hours), reflecting renal clearance of the free radiotracer. This half-life supports imaging within 2-4 hours post-injection for optimal bone-to-background ratios. |
| Protein binding | Approximately 50-60% bound to plasma proteins, predominantly albumin and transferrin. Binding is reversible and does not significantly affect biodistribution. |
| Volume of Distribution | The apparent volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution into extracellular fluid and bone, with limited intracellular penetration. |
| Bioavailability | Not applicable for the intravenous route. No oral formulation exists; bioavailability is 100% after IV administration. |
| Onset of Action | Intravenous administration: skeletal uptake begins within minutes, with peak bone uptake at 2-4 hours post-injection, corresponding to the onset of diagnostic imaging utility. |
| Duration of Action | Effective imaging window is 2-4 hours post-injection, with adequate bone uptake persisting for up to 24 hours. Beyond 24 hours, background clearance reduces image quality; delayed imaging (e.g., 24 hours) may be used for renal failure cases. |
100 mg intravenously every 8 hours over 30 minutes.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 30-50 mL/min: 100 mg every 12 hours; CrCl 15-29 mL/min: 100 mg every 24 hours; CrCl <15 mL/min or hemodialysis: 100 mg every 48 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 50 mg every 8 hours; Child-Pugh Class C: 50 mg every 12 hours. |
| Pediatric use | 2 mg/kg intravenously every 8 hours; maximum 100 mg per dose. |
| Geriatric use | Start at 50 mg every 8 hours; titrate based on renal function and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEOSCAN (NEOSCAN).
| Breastfeeding | Technetium-99m sestamibi is excreted in breast milk. M/P ratio not established. Advise interruption of breastfeeding for at least 24 hours post-administration to reduce infant radiation exposure. |
| Teratogenic Risk | NEOSCAN (technetium-99m sestamibi) is a radiopharmaceutical. No human data on teratogenicity; theoretical risk of fetal radiation exposure. Use only if benefit outweighs risk. First trimester: avoid if possible due to radiosensitivity. Second/third trimester: minimal risk at standard diagnostic doses (<5 rad). |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to any component of the product."]
| Precautions | ["Radiation exposure: Similar to other radiopharmaceuticals, carries a risk of radiation exposure to patients and handlers.","Hypersensitivity reactions: Rare allergic reactions may occur.","Interpretation limitations: Results should be correlated with clinical findings and other diagnostic procedures."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal vital signs during injection. Fetal radiation dose estimate (if pregnant) should be calculated per institutional protocol. No specific fetal monitoring required post-exposure. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data not available; radiation exposure to gonads may be negligible at diagnostic doses. |